Novartis Fact Sheet
About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas.
In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 125,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world.
Company headquarters
|
|
Novartis International AG
|
Share monitor
Q3 2018 results
| Q3 2018 (USD m) |
Q3 2017 (USD m) |
% change (USD) |
|
|---|---|---|---|
| Net sales | 12,779 | 12,413 | 3 |
2017 annual results
| FY 2017 (USD m) |
FY 2016 (USD m) |
% change (USD) |
|
|---|---|---|---|
| Net sales | 49,109 | 48,518 | 1 |
Find annual, quarterly results and more in our financial data section
Chief Executive Officer
 |
Vasant (Vas) Narasimhan, M.D.
|
Corporate Responsibility
Access to healthcare
- Through our business, we make an important contribution to society: We discover and develop innovative healthcare products, targeting unmet medical needs. Novartis medicines reach nearly 1 billion people each year.
- In 2017, our access-to-healthcare programs reached nearly 46 million patients with Novartis products and nearly 15 million people with health education, infrastructure development and other programs.
Learn more about our efforts to expand access to healthcare
Our complementary healthcare businesses address the changing needs of patients and societies worldwide. With innovative pharmaceuticals at the core, we are also a global leader in eye care and generics products.
Top products
| Product | Full Year 2017 Product Sales | 2017 franchise | |
|---|---|---|---|
| USD m | variance in cc | ||
| Gilenya | 3,185 | 2% | Neuroscience |
| Cosentyx | 2,071 | 82% | Immunology and Dermatology |
| Gleevec/Glivec | 1,943 | 41% | Oncology |
| Lucentis | 1,888 | 4% | Ophthalmology |
| Tasigna | 1,841 | 9% | Oncology |
Locations
More than 23,000 scientists, physicians, and business professionals are located in Research and Development sites in more than 80 countries worldwide.
Novartis #3 corporate institution in Nature Index 2018 ranking
The Nature Index 2018 ranking, published by Nature Research, ranks various institutions (corporate, academic, government, NPO/NGO) based on contributions to articles published in a group of 82 selected science journals. Novartis maintained its #3 ranking from 2017.
Novartis ranks #3 in 2018 Pharmaceutical Innovation Index
IdeaPharma’s PII ranks companies on their ability to bring products from early development to market and commercialize them successfully. Novartis moved up 9 spots, from #12 in 2017.
Novartis moves up 4 places to 64 in 2018 Global 100 Most Sustainable Corporations list by Corporate Knights
The Corporate Knights list is recognized as one of the leading sustainability rankings worldwide and inclusion is determined using up to 14 quantitative social, environmental and governance indicators, such as innovation capacity, employee turnover and leadership diversity.
Fast Company’s 2018 World's Most Innovative Companies list
Novartis has been named #1 most innovative biotech company and ranked #21 overall by Fast Company. The ranking identifies the most notable innovations of the year.
Fortune's Most Admired Pharmaceutical Companies 2018
Novartis has been ranked #3 by Fortune magazine as one of the most admired pharmaceutical companies in the world — our 14th consecutive year in the top three.
CDP rates Novartis A on Water and A- in Climate in 2017
Novartis is one of 73 companies worldwide to make CDP’s Water A List in 2017. We also maintained an A- rating and are recognized among category leaders in healthcare in the 2017 CDP Climate Score.
Fortune’s Change the World List 2017
Novartis ranked #4 in Fortune’s list of companies that are doing well by doing good. The list recognizes companies that have a positive social impact through activities that are part of their core business strategy.
| For further information regarding Novartis please contact: | |||||||||
|
|
||||||||
|
|
||||||||